Fukuhara Naoko, Tanino Yoshinori, Sato Suguru, Fukuhara Atsuro, Uematsu Manabu, Nikaido Takefumi, Misa Kenichi, Sato Yasuko, Saito Junpei, Wang Xintao, Munakata Mitsuru
Department of Pulmonary Medicine, Fukushima Medical University.
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Sep 14;32(3):265-70.
Krebs von den Lungen-6 (KL-6) is a high-molecular-weight glycoprotein which is elevated in serum of patients with interstitial pneumonia (IP). Serum KL-6 level is clinically used for the diagnosis of IP as well as the evaluation of its disease activity. KL-6 is originally identified when exploring novel soluble antigens in patients with lung cancer, and is known to be elevated in patients with several malignant tumors. The risk of malignant tumors is high in IP patients with polymyositis and dermatomyositis (PM/DM), and follow-up of KL-6 levels may allow earlier detection of such tumors. However, to date, there are only a few reports showing the usefulness of following-up serum KL-6 levels for finding malignant tumors in IP patients with PM/DM. Here, we described the first patient in whom increased serum KL-6 led to the diagnosis of colon cancer during follow-up of DM-associated IP.
克雷伯氏肺-6(KL-6)是一种高分子量糖蛋白,在间质性肺炎(IP)患者的血清中水平升高。血清KL-6水平在临床上用于IP的诊断及其疾病活动度的评估。KL-6最初是在探索肺癌患者的新型可溶性抗原时被鉴定出来的,并且已知在几种恶性肿瘤患者中水平升高。患有多发性肌炎和皮肌炎(PM/DM)的IP患者发生恶性肿瘤的风险很高,对KL-6水平进行随访可能有助于更早地发现此类肿瘤。然而,迄今为止,仅有少数报告显示随访血清KL-6水平对发现患有PM/DM的IP患者中的恶性肿瘤有用。在此,我们描述了第一例在与DM相关的IP随访期间,血清KL-6升高导致结肠癌诊断的患者。